USA flag logo/image

An Official Website of the United States Government

A Lyme disease vaccine using newly identified in-vivo expressed antigens

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R43AI096628
Solicitation Year:
2013
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-123
Small Business Information
L2 DIAGNOSTICS, LLC
BOX 8175 NEW HAVEN, CT -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: A Lyme disease vaccine using newly identified in-vivo expressed antigens
Agency: HHS
Contract: 1R43AI096628-01A1
Award Amount: $595,406.00
 

Abstract:

DESCRIPTION (provided by applicant): Lyme disease is the most common arthropod-borne disease in the United States, with over 38,000 confirmed and probable cases reported in 2009. The causative agent of Lyme disease is the spirochete Borrelia burgdorferi, which is transmitted by the tick of the Ixodes scapularis tick. The number of Lyme disease cases has tripled over the past fifteen years. The disease is sometimes difficult to diagnose in its early stages, leading to delayed treatment. Patients who are nottreated in a timely fashion may suffer from severe, long lasting symptoms, and fail to respond to antibiotic therapy. Control measures designed to prevent contact with ticks are not sufficient to prevent the disease. We propose to develop a vaccine to control Lyme disease in human populations. After being injected into the skin of a mammalian host, Borrelia bacteria multiply locally before disseminating to other organs. We have now for the first time been able to isolate sufficient amounts of bacteria fromthe skin of infected mice in order to identify proteins expressed at high levels in the skin. We believe that immunization against these proteins, which are expressed in the early acute phase of Lyme disease, will be highly effective in preventing bacterial proliferation and dissemination. Fifteen membrane proteins identified in the skin of infected mice will be produced in recombinant form using standard bacterial expression systems. These proteins are conserved among strains of Borrelia, which should ensure that our vaccine is effective against all strains of circulating Borrelia. Each antigen will then be administered to C57Bl/6 mice in the presence of an adjuvant. We will demonstrate that this immunization protocol results in the appearance of anti-Borrelia antibodies. Immunized animals will then be challenged with 104 live Borrelia spirochetes. Twenty-one days after challenge we will collect tissue samples to determine whether they contain live Borrelia. We will also quantitatively detect the presence ofBorrelia DNA in these samples. A protein antigen will be considered protective (1) if spirochetes cannot be cultured from the tissues of immunized mice after challenge or (2) if the bacterial load, determined from the amount of DNA detected, is reduced byat least 50%. At the conclusion of these experiments we will select up to four antigens for further study. Phase II experiments will determine the optimal formulation and method of delivery. We will also examine whether antigens can be combined to providefull protection against Borrelia. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Lyme disease is a bacterial disease transmitted by ticks. It is very common in the Northeast and the Midwest of the United States. The disease is sometimes difficult to diagnose, leaving patients exposed to more severe and long lasting symptoms. We propose to develop a vaccine that would prevent Lyme disease in human populations.

Principal Investigator:

Michel Ledizet
203-503-0383
mledizet@L2dx.com

Business Contact:

Martin J. Mattessich
203-393-9439
mmattessich@L2dx.com
Small Business Information at Submission:

L2 DIAGNOSTICS, LLC
BOX 8175 NEW HAVEN, CT -

EIN/Tax ID: 106150994
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No